{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:23:56Z","timestamp":1790792636606,"version":"4.1.0"},"reference-count":95,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurologic Clinics"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.ncl.2018.09.007","type":"journal-article","created":{"date-parts":[[2018,11,21]],"date-time":"2018-11-21T11:14:30Z","timestamp":1542798870000},"page":"17-30","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Management of Demyelinating Disorders in Pregnancy"],"prefix":"10.1016","volume":"37","author":[{"given":"Tamara B.","family":"Kaplan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ncl.2018.09.007_bib1","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1177\/1352458513519181","article-title":"The role of gender and sex hormones in determining the onset and outcome of multiple sclerosis","volume":"20","author":"Bove","year":"2014","journal-title":"Mult Scler"},{"key":"10.1016\/j.ncl.2018.09.007_bib2","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S0002-9378(16)39356-5","article-title":"Pregnancy and multiple sclerosis","volume":"55","author":"Douglass","year":"1948","journal-title":"Am J Obstet Gynecol"},{"issue":"5","key":"10.1016\/j.ncl.2018.09.007_bib3","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1056\/NEJM199807303390501","article-title":"Rate of pregnancy-related relapse in multiple sclerosis","volume":"339","author":"Confavreux","year":"1998","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.ncl.2018.09.007_bib4","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1093\/brain\/awh152","article-title":"Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse","volume":"127","author":"Vukusic","year":"2004","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.ncl.2018.09.007_bib5","doi-asserted-by":"crossref","first-page":"113","DOI":"10.7224\/1537-2073.2012-048","article-title":"The incidence and prevalence of neuromyelitis optica: a systematic review","volume":"15","author":"Marrie","year":"2013","journal-title":"Int J MS Care"},{"issue":"9","key":"10.1016\/j.ncl.2018.09.007_bib6","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1001\/archneurol.2012.314","article-title":"Epidemiology of neuromyelitis optica in the United States: a multicenter analysis","volume":"69","author":"Mealy","year":"2012","journal-title":"Arch Neurol"},{"issue":"9","key":"10.1016\/j.ncl.2018.09.007_bib7","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","article-title":"The spectrum of neuromyelitis optica","volume":"6","author":"Wingerchuk","year":"2007","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.ncl.2018.09.007_bib8","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1600-0404.2004.00270.x","article-title":"The relapse rate of multiple sclerosis changes during pregnancy: a cohort study","volume":"110","author":"Salemi","year":"2004","journal-title":"Acta Neurol Scand"},{"issue":"2","key":"10.1016\/j.ncl.2018.09.007_bib9","first-page":"142","article-title":"Pregnancy and multiple sclerosis\u2014outcomes analysis 2003-2011","volume":"78","author":"Hanul\u00edkov\u00e1","year":"2013","journal-title":"Ceska Gynekol"},{"issue":"5","key":"10.1016\/j.ncl.2018.09.007_bib10","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1600-0404.1994.tb02728.x","article-title":"Effect of pregnancy on the prognosis for multiple sclerosis. A 5-year follow up investigation","volume":"90","author":"Stenager","year":"1994","journal-title":"Acta Neurol Scand"},{"issue":"3","key":"10.1016\/j.ncl.2018.09.007_bib11","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1067\/mob.2002.120502","article-title":"Birth outcomes and need for hospitalization after delivery among women with multiple sclerosis","volume":"186","author":"Mueller","year":"2002","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.ncl.2018.09.007_bib12","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.clim.2013.02.001","article-title":"Artificial reproductive techniques in multiple sclerosis","volume":"149","author":"Hellwig","year":"2013","journal-title":"Clin Immunol"},{"issue":"1","key":"10.1016\/j.ncl.2018.09.007_bib13","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1177\/1352458514540843","article-title":"Serum anti-M\u00fcllerian hormone levels in reproductive-age women with relapsing\u2013remitting multiple sclerosis","volume":"21","author":"Th\u00f6ne","year":"2015","journal-title":"Mult Scler"},{"issue":"4","key":"10.1016\/j.ncl.2018.09.007_bib14","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1365-2796.1989.tb01387.x","article-title":"Serum sex hormone and gonadotropin concentrations in premenopausal women with multiple sclerosis","volume":"226","author":"Grinsted","year":"1989","journal-title":"J\u00a0Intern Med"},{"issue":"4","key":"10.1016\/j.ncl.2018.09.007_bib15","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s10072-006-0676-x","article-title":"Fertility in patients with multiple sclerosis: current knowledge and future perspectives","volume":"27","author":"Cavalla","year":"2006","journal-title":"Neurol Sci"},{"issue":"6","key":"10.1016\/j.ncl.2018.09.007_bib16","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1097\/AOG.0000000000000541","article-title":"Management of multiple sclerosis during pregnancy and the reproductive years: a systematic review","volume":"124","author":"Bove","year":"2014","journal-title":"Obstet Gynecol"},{"issue":"11","key":"10.1016\/j.ncl.2018.09.007_bib17","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/nrneurol.2012.198","article-title":"The initiation and prevention of multiple sclerosis","volume":"8","author":"Ascherio","year":"2012","journal-title":"Nat Rev Neurol"},{"issue":"5","key":"10.1016\/j.ncl.2018.09.007_bib18","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1001\/jamaneurol.2015.4800","article-title":"Vitamin D status during pregnancy and risk of multiple sclerosis in offspring of women in the Finnish maternity cohort","volume":"73","author":"Munger","year":"2016","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.ncl.2018.09.007_bib19","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/AOG.0b013e318227f06b","article-title":"ACOG Committee opinion no. 495: vitamin D: screening and supplementation during pregnancy","volume":"118","author":"ACOG Committee on Obstetric Practice","year":"2011","journal-title":"Obstet Gynecol"},{"issue":"8","key":"10.1016\/j.ncl.2018.09.007_bib20","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1212\/01.wnl.0000208521.10685.a6","article-title":"Increase in multiple sclerosis relapse rate following in\u00a0vitro fertilization","volume":"66","author":"Laplaud","year":"2006","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.ncl.2018.09.007_bib21","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1136\/jnnp-2012-302235","article-title":"Increased risk of multiple sclerosis relapse after in\u00a0vitro fertilisation","volume":"83","author":"Michel","year":"2012","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"5","key":"10.1016\/j.ncl.2018.09.007_bib22","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1002\/ana.23745","article-title":"Increase in multiple sclerosis activity after assisted reproduction technology","volume":"72","author":"Correale","year":"2012","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1016\/j.ncl.2018.09.007_bib23","first-page":"592","article-title":"Increased MS relapse rate during assisted reproduction technique","volume":"255","author":"Hellwig","year":"2008","journal-title":"J\u00a0Neurol"},{"issue":"2","key":"10.1016\/j.ncl.2018.09.007_bib24","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000177937","article-title":"Increase in relapse rate during assisted reproduction technique in patients with multiple sclerosis","volume":"61","author":"Hellwig","year":"2009","journal-title":"Eur Neurol"},{"key":"10.1016\/j.ncl.2018.09.007_bib25","unstructured":"Bove R, Rankin K, Lin C, et\u00a0al. Assisted reproductive technologies and relapse risk: a new case series, and pooled analysis of existing studies. Poster presented at ECTRIMS 2017. Paris, France, October 25\u201328, 2017."},{"issue":"1, Neurology of Pregnancy","key":"10.1016\/j.ncl.2018.09.007_bib26","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1212\/01.CON.0000443835.10508.2b","article-title":"Neuroradiology in women of childbearing age","volume":"20","author":"Bove","year":"2014","journal-title":"Continuum (Minneap Minn)"},{"issue":"8","key":"10.1016\/j.ncl.2018.09.007_bib27","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1177\/1933719108324138","article-title":"Multiple sclerosis and reproductive risks in women","volume":"15","author":"Argyriou","year":"2008","journal-title":"Reprod Sci"},{"issue":"1","key":"10.1016\/j.ncl.2018.09.007_bib28","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/tera.1420510107","article-title":"Teratogenic potential of corticosteroids in humans","volume":"51","author":"Fraser","year":"1995","journal-title":"Teratology"},{"issue":"3","key":"10.1016\/j.ncl.2018.09.007_bib29","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/(SICI)1096-8628(19990917)86:3<242::AID-AJMG9>3.0.CO;2-U","article-title":"Maternal corticosteroid use and risk of selected congenital anomalies","volume":"86","author":"Carmichael","year":"1999","journal-title":"Am J Med Genet A"},{"issue":"6","key":"10.1016\/j.ncl.2018.09.007_bib30","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/bdra.23248","article-title":"Corticosteroid use and risk of orofacial clefts","volume":"100","author":"Skuladottir","year":"2014","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"issue":"2","key":"10.1016\/j.ncl.2018.09.007_bib31","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/MJT.0b013e3182491e02","article-title":"Use of corticosteroids in early pregnancy is not associated with risk of oral clefts and other congenital malformations in offspring","volume":"21","author":"Bay Bj\u00f8rn","year":"2014","journal-title":"Am J Ther"},{"issue":"9","key":"10.1016\/j.ncl.2018.09.007_bib32","first-page":"1133","article-title":"Effect of intravenous immunoglobulin treatment on pregnancy and postpartum-related relapses in multiple sclerosis","volume":"251","author":"Achiron","year":"2004","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.ncl.2018.09.007_bib33","first-page":"819216","article-title":"What do healthcare providers advise women with multiple sclerosis regarding pregnancy?","volume":"2014","author":"Wundes","year":"2014","journal-title":"Mult Scler Int"},{"issue":"3","key":"10.1016\/j.ncl.2018.09.007_bib34","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1177\/1756285616631897","article-title":"Management of women with multiple sclerosis through pregnancy and after childbirth","volume":"9","author":"Coyle","year":"2016","journal-title":"Ther Adv Neurol Disord"},{"issue":"20","key":"10.1016\/j.ncl.2018.09.007_bib35","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1212\/WNL.0b013e3181fd62bb","article-title":"Pregnancy and fetal outcomes after interferon-\u03b2 exposure in multiple sclerosis","volume":"75","author":"Amato","year":"2010","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.ncl.2018.09.007_bib36","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1212\/01.wnl.0000180575.77021.c4","article-title":"The reproductive effects of beta interferon therapy in pregnancy A longitudinal cohort","volume":"65","author":"Boskovic","year":"2005","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.ncl.2018.09.007_bib37","first-page":"1250","article-title":"Is in utero early-exposure to interferon beta a risk factor for pregnancy outcomes in multiple sclerosis?","volume":"255","author":"Patti","year":"2008","journal-title":"J\u00a0Neurol"},{"issue":"6","key":"10.1016\/j.ncl.2018.09.007_bib38","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1177\/1352458516634872","article-title":"Interferon-beta exposure during first trimester is safe in women with multiple sclerosis\u2014a prospective cohort study from the German Multiple Sclerosis and Pregnancy Registry","volume":"22","author":"Thiel","year":"2016","journal-title":"Mult Scler"},{"issue":"5","key":"10.1016\/j.ncl.2018.09.007_bib39","doi-asserted-by":"crossref","first-page":"e004536","DOI":"10.1136\/bmjopen-2013-004536","article-title":"Final results from the Betaseron (interferon \u03b2-1b) Pregnancy Registry: a prospective observational study of birth defects and pregnancy-related adverse events","volume":"4","author":"Coyle","year":"2014","journal-title":"BMJ Open"},{"issue":"11","key":"10.1016\/j.ncl.2018.09.007_bib40","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1212\/WNL.0b013e3182698c64","article-title":"Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review","volume":"79","author":"Lu","year":"2012","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.ncl.2018.09.007_bib41","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1212\/01.wnl.0000182147.73071.2c","article-title":"Interferon beta babies","volume":"65","author":"Waubant","year":"2005","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.ncl.2018.09.007_bib42","first-page":"969","article-title":"Long-term use of glatiramer acetate by 11 pregnant women with multiple sclerosis","volume":"24","author":"Fragoso","year":"2010","journal-title":"CNS Drugs"},{"issue":"6","key":"10.1016\/j.ncl.2018.09.007_bib43","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1177\/1352458515623366","article-title":"Glatiramer acetate during early pregnancy: a prospective cohort study","volume":"22","author":"Herbstritt","year":"2016","journal-title":"Mult Scler"},{"key":"10.1016\/j.ncl.2018.09.007_bib44","doi-asserted-by":"crossref","unstructured":"Neudorfer O, Melamed-Gal S, Baruch P. Pregnancy outcomes in patients with multiple sclerosis and exposure to branded glatiramer acetate during all three trimesters. Poster presented at ECTRIMS 2017. Paris, France, October 25\u201328, 2017.","DOI":"10.26226\/morressier.59a3eda9d462b8028d895597"},{"issue":"2","key":"10.1016\/j.ncl.2018.09.007_bib45","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s40120-015-0033-1","article-title":"Delayed-release dimethyl fumarate and pregnancy: preclinical studies and pregnancy outcomes from clinical trials and postmarketing experience","volume":"4","author":"Gold","year":"2015","journal-title":"Neurol Ther"},{"key":"10.1016\/j.ncl.2018.09.007_bib46","series-title":"Tecfidera, dimethy; fumarte [package insert] Cambridge,","year":"2014"},{"issue":"8","key":"10.1016\/j.ncl.2018.09.007_bib47","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1212\/WNL.0000000000000137","article-title":"Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis","volume":"82","author":"Karlsson","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2018.09.007_bib48","series-title":"Health issues in women with multiple sclerosis","author":"Houtchens","year":"2017"},{"key":"10.1016\/j.ncl.2018.09.007_bib49","unstructured":"Collins W, Francis G, Koren G, et\u00a0al. Lack of interaction between fingolimod (FTY720) and oral contraceptives, and pregnancy experience in the clinical program of fingolimod in multiple sclerosis. Paper presented at: Neurology2011."},{"key":"10.1016\/j.ncl.2018.09.007_bib50","doi-asserted-by":"crossref","first-page":"513160","DOI":"10.1155\/2014\/513160","article-title":"Multiple sclerosis and pregnancy: current considerations","volume":"2014","author":"Buraga","year":"2014","journal-title":"ScientificWorldJournal"},{"issue":"7","key":"10.1016\/j.ncl.2018.09.007_bib51","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1001\/jamaneurol.2016.0826","article-title":"Rebound syndrome in patients with multiple sclerosis after cessation of fingolimod treatment","volume":"73","author":"Hatcher","year":"2016","journal-title":"JAMA Neurol"},{"issue":"5","key":"10.1016\/j.ncl.2018.09.007_bib52","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/nrneurol.2015.53","article-title":"Multiple sclerosis and pregnancy in the 'treatment era","volume":"11","author":"Vukusic","year":"2015","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.ncl.2018.09.007_bib53","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/1096-9926(200102)63:2<106::AID-TERA1017>3.0.CO;2-R","article-title":"Teratogen update\u2014reproductive risks of leflunomide (Arava TM); a pyrimidine synthesis inhibitor: counseling women taking leflunomide before or during pregnancy and men taking leflunomide who are contemplating fathering a child","volume":"63","author":"Brent Robert","year":"2001","journal-title":"Teratology"},{"issue":"7","key":"10.1016\/j.ncl.2018.09.007_bib54","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1002\/art.34419","article-title":"Pregnancy outcome in women exposed to leflunomide before or during pregnancy","volume":"64","author":"Cassina","year":"2012","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ncl.2018.09.007_bib55","series-title":"AUBAGIO prescribing information","year":"2012"},{"issue":"7","key":"10.1016\/j.ncl.2018.09.007_bib56","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1001\/jamaneurol.2014.209","article-title":"Natalizumab use during the third trimester of pregnancy","volume":"71","author":"Haghikia","year":"2014","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.ncl.2018.09.007_bib57","unstructured":"K\u00fcmpfel T, Thiel S, Meinl I, et\u00a0al. Long-term exposure to natalizumab during pregnancy\u2014a prospective case series from the German Multiple Sclerosis and Pregnancy Registry. Poster presented at ECTRIMS 2017. Paris, France, Oct 25\u201328, 2017."},{"issue":"4","key":"10.1016\/j.ncl.2018.09.007_bib58","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s13311-017-0557-4","article-title":"Ocrelizumab and other CD20+ B-cell-depleting therapies in multiple sclerosis","volume":"14","author":"Gelfand","year":"2017","journal-title":"Neurotherapeutics"},{"issue":"1","key":"10.1016\/j.ncl.2018.09.007_bib59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2008\/271363","article-title":"Rituximab administration in third trimester of pregnancy suppresses neonatal B-cell development","volume":"2008","author":"Klink","year":"2008","journal-title":"Clin Dev Immunol"},{"issue":"5","key":"10.1016\/j.ncl.2018.09.007_bib60","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1182\/blood-2010-07-295444","article-title":"Pregnancy outcomes after maternal exposure to rituximab","volume":"117","author":"Chakravarty","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ncl.2018.09.007_bib61","series-title":"Ocrelizumab [package insert]","year":"2017"},{"issue":"16 Supplement","key":"10.1016\/j.ncl.2018.09.007_bib62","first-page":"S24","article-title":"Pregnancy outcomes in patients with RRMS who received alemtuzumab in the clinical development program (S24. 008)","volume":"86","author":"Oh","year":"2016","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.ncl.2018.09.007_bib63","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1080\/14740338.2017.1311321","article-title":"Treatment of multiple sclerosis during pregnancy\u2013safety considerations","volume":"16","author":"Th\u00f6ne","year":"2017","journal-title":"Expert Opin Drug Saf"},{"issue":"2","key":"10.1016\/j.ncl.2018.09.007_bib64","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.clim.2013.01.008","article-title":"Effects of pregnancy and breastfeeding on the multiple sclerosis disease course","volume":"149","author":"Langer-Gould","year":"2013","journal-title":"Clin Immunol"},{"issue":"10","key":"10.1016\/j.ncl.2018.09.007_bib65","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/jamaneurol.2015.1806","article-title":"Exclusive breastfeeding and the effect on postpartum multiple sclerosis relapses","volume":"72","author":"Hellwig","year":"2015","journal-title":"JAMA Neurol"},{"issue":"2","key":"10.1016\/j.ncl.2018.09.007_bib66","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1212\/WNL.0b013e318224afc9","article-title":"Breastfeeding is not related to postpartum relapses in multiple sclerosis","volume":"77","author":"Portaccio","year":"2011","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.ncl.2018.09.007_bib67","first-page":"2246","article-title":"Breastfeeding and multiple sclerosis relapses: a meta-analysis","volume":"259","author":"Pakpoor","year":"2012","journal-title":"J\u00a0Neurol"},{"issue":"2","key":"10.1016\/j.ncl.2018.09.007_bib68","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1089\/bfm.2011.0044","article-title":"Transfer of interferon \u03b2-1a into human breastmilk","volume":"7","author":"Hale","year":"2012","journal-title":"Breastfeed Med"},{"issue":"4","key":"10.1016\/j.ncl.2018.09.007_bib69","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1007\/s13311-017-0562-7","article-title":"Pregnancy: effect on multiple sclerosis, treatment considerations, and breastfeeding","volume":"14","author":"Voskuhl","year":"2017","journal-title":"Neurotherapeutics"},{"issue":"Suppl. 1","key":"10.1016\/j.ncl.2018.09.007_bib70","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1159\/000367640","article-title":"Pregnancy in multiple sclerosis","volume":"72","author":"Hellwig","year":"2014","journal-title":"Eur Neurol"},{"key":"10.1016\/j.ncl.2018.09.007_bib71","first-page":"6527458","article-title":"Management of multiple sclerosis in the breastfeeding mother","volume":"2016","author":"Almas","year":"2016","journal-title":"Mult Scler Int"},{"issue":"2","key":"10.1016\/j.ncl.2018.09.007_bib72","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1177\/0890334414566237","article-title":"Transfer of natalizumab into breast milk in a mother with multiple sclerosis","volume":"31","author":"Baker","year":"2015","journal-title":"J\u00a0Hum Lact"},{"issue":"1","key":"10.1016\/j.ncl.2018.09.007_bib73","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/toxsci\/kfq316","article-title":"Developmental immunotoxicology assessment of rituximab in cynomolgus monkeys","volume":"119","author":"Vaidyanathan","year":"2010","journal-title":"Toxicol Sci"},{"issue":"4","key":"10.1016\/j.ncl.2018.09.007_bib74","doi-asserted-by":"crossref","first-page":"442","DOI":"10.3390\/nu3040442","article-title":"Perspectives on immunoglobulins in colostrum and milk","volume":"3","author":"Hurley","year":"2011","journal-title":"Nutrients"},{"issue":"6","key":"10.1016\/j.ncl.2018.09.007_bib75","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1093\/rheumatology\/kex039","article-title":"Low level of rituximab in human breast milk in a patient treated during lactation","volume":"56","author":"Bragnes","year":"2017","journal-title":"Rheumatology"},{"issue":"5","key":"10.1016\/j.ncl.2018.09.007_bib76","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1191\/1352458504ms1079sr","article-title":"Intravenous corticosteroids in the postpartum period for reduction of acute exacerbations in multiple sclerosis","volume":"10","author":"De Seze","year":"2004","journal-title":"Mult Scler"},{"issue":"2","key":"10.1016\/j.ncl.2018.09.007_bib77","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1177\/0890334415570970","article-title":"Transfer of methylprednisolone into breast milk in a mother with multiple sclerosis","volume":"31","author":"Cooper","year":"2015","journal-title":"J\u00a0Hum Lact"},{"issue":"1","key":"10.1016\/j.ncl.2018.09.007_bib78","first-page":"25","article-title":"Intravenous immunoglobulin treatment in the prevention of childbirth-associated acute exacerbations in multiple sclerosis: a pilot study","volume":"243","author":"Achiron","year":"1996","journal-title":"J\u00a0Neurol"},{"issue":"2","key":"10.1016\/j.ncl.2018.09.007_bib79","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ijgo.2016.01.008","article-title":"The effect of postpartum intravenous immunoglobulins on the relapse rate among patients with multiple sclerosis","volume":"134","author":"Brandt-Wouters","year":"2016","journal-title":"Int J Gynaecol Obstet"},{"issue":"7","key":"10.1016\/j.ncl.2018.09.007_bib80","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1177\/1352458515572406","article-title":"Demographic and clinical features of neuromyelitis optica: a review","volume":"21","author":"Pandit","year":"2015","journal-title":"Mult Scler"},{"issue":"8","key":"10.1016\/j.ncl.2018.09.007_bib81","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1001\/archneurol.2012.249","article-title":"Effects of age and sex on aquaporin-4 autoimmunity","volume":"69","author":"Quek","year":"2012","journal-title":"Arch Neurol"},{"issue":"4","key":"10.1016\/j.ncl.2018.09.007_bib82","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"Lennon","year":"2005","journal-title":"J\u00a0Exp Med"},{"issue":"9","key":"10.1016\/j.ncl.2018.09.007_bib83","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1001\/jamaneurol.2013.3124","article-title":"Aquaporin 4 expression and tissue susceptibility to neuromyelitis optica","volume":"70","author":"Matiello","year":"2013","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.ncl.2018.09.007_bib84","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000004681","article-title":"High risk of postpartum relapses in neuromyelitis optica spectrum disorder","author":"Klawiter","year":"2017","journal-title":"Neurology"},{"issue":"16","key":"10.1016\/j.ncl.2018.09.007_bib85","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1212\/WNL.0b013e318250d812","article-title":"Influence of pregnancy on neuromyelitis optica spectrum disorder","volume":"78","author":"Kim","year":"2012","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.ncl.2018.09.007_bib86","first-page":"2614","article-title":"Neuromyelitis optica and pregnancy","volume":"260","author":"Fragoso","year":"2013","journal-title":"J\u00a0Neurol"},{"issue":"1","key":"10.1016\/j.ncl.2018.09.007_bib87","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1212\/WNL.0000000000002208","article-title":"Pregnancy outcomes in aquaporin-4\u2013positive neuromyelitis optica spectrum disorder","volume":"86","author":"Nour","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2018.09.007_bib88","first-page":"355","article-title":"Systemic lupus erythematosus and pregnancy","volume":"43","author":"Reichlin","year":"1998","journal-title":"J\u00a0Reprod Med"},{"issue":"6","key":"10.1016\/j.ncl.2018.09.007_bib89","doi-asserted-by":"crossref","first-page":"e288","DOI":"10.1212\/NXI.0000000000000288","article-title":"Immunology of neuromyelitis optica during pregnancy","volume":"3","author":"Davoudi","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.ncl.2018.09.007_bib90","series-title":"A\u00a0woman with acute myelopathy in pregnancy: case outcome","author":"Reu\u00df","year":"2009"},{"issue":"4","key":"10.1016\/j.ncl.2018.09.007_bib91","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.msard.2012.06.002","article-title":"Treatment of neuromyelitis optica: review and recommendations","volume":"1","author":"Kimbrough","year":"2012","journal-title":"Mult Scler Relat Disord"},{"issue":"11","key":"10.1016\/j.ncl.2018.09.007_bib92","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1001\/archneur.65.11.noc80069","article-title":"Treatment of neuromyelitis optica with rituximab","volume":"65","author":"Jacob","year":"2008","journal-title":"Arch Neurol"},{"issue":"8","key":"10.1016\/j.ncl.2018.09.007_bib93","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1177\/1352458509106512","article-title":"Course of neuromyelitis optica during inadvertent pregnancy in a patient treated with rituximab","volume":"15","author":"Pellkofer","year":"2009","journal-title":"Mult Scler"},{"issue":"6","key":"10.1016\/j.ncl.2018.09.007_bib94","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1586\/eci.10.77","article-title":"Treatment of cancer during pregnancy with monoclonal antibodies: a real challenge","volume":"6","author":"Azim","year":"2010","journal-title":"Expert Rev Clin Immunol"},{"issue":"5","key":"10.1016\/j.ncl.2018.09.007_bib95","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1177\/1352458507086103","article-title":"The motherhood choice: themes arising in the decision-making process for women with multiple sclerosis","volume":"14","author":"Prunty","year":"2008","journal-title":"Mult Scler"}],"container-title":["Neurologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733861918312568?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733861918312568?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T10:15:41Z","timestamp":1760004941000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733861918312568"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":95,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S0733861918312568"],"URL":"https:\/\/doi.org\/10.1016\/j.ncl.2018.09.007","relation":{},"ISSN":["0733-8619"],"issn-type":[{"value":"0733-8619","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Demyelinating Disorders in Pregnancy","name":"articletitle","label":"Article Title"},{"value":"Neurologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ncl.2018.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}